

Global Tumor Necrosis Factor Inhibitors Market Growth 2022-2028

<https://marketpublishers.com/r/G8F94D265A31EN.html>

Date: January 2022

Pages: 103

Price: US\$ 3,660.00 (Single User License)

ID: G8F94D265A31EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

As the global economy mends, the 2021 growth of Tumor Necrosis Factor Inhibitors will have significant change from previous year. According to our (LP Information) latest study, the global Tumor Necrosis Factor Inhibitors market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Tumor Necrosis Factor Inhibitors market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Tumor Necrosis Factor Inhibitors market is expected at value of US\$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Tumor Necrosis Factor Inhibitors market, reaching US\$ million by the year 2028. As for the Europe Tumor Necrosis Factor Inhibitors landscape, Germany is projected to reach US\$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Tumor Necrosis Factor Inhibitors players cover EPIRUS Biopharmaceuticals, Bionovis, CASI Pharmaceuticals, and Janssen Biotech, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Necrosis Factor Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast

to 2028 in section 12.6

Humira

Enbrel

Remicade

Others

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

Alzheimer's Diseases

Parkinson's Diseases

Ischemic Stroke

Multiple Sclerosis

Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include

EPIRUS Biopharmaceuticals

Bionovis

CASI Pharmaceuticals

Janssen Biotech

Momenta Pharmaceuticals

GlaxoSmithKline

HanAll Biopharma

Intas Pharmaceuticals

LEO Pharma

Dexa Medica

LG Life Sciences

MedImmune

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Tumor Necrosis Factor Inhibitors Annual Sales 2017-2028
 - 2.1.2 World Current & Future Analysis for Tumor Necrosis Factor Inhibitors by Geographic Region, 2017, 2022 & 2028
 - 2.1.3 World Current & Future Analysis for Tumor Necrosis Factor Inhibitors by Country/Region, 2017, 2022 & 2028
- 2.2 Tumor Necrosis Factor Inhibitors Segment by Type
 - 2.2.1 Humira
 - 2.2.2 Enbrel
 - 2.2.3 Remicade
 - 2.2.4 Others
- 2.3 Tumor Necrosis Factor Inhibitors Sales by Type
 - 2.3.1 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2022)
 - 2.3.2 Global Tumor Necrosis Factor Inhibitors Revenue and Market Share by Type (2017-2022)
 - 2.3.3 Global Tumor Necrosis Factor Inhibitors Sale Price by Type (2017-2022)
- 2.4 Tumor Necrosis Factor Inhibitors Segment by Application
 - 2.4.1 Alzheimer's Diseases
 - 2.4.2 Parkinson's Diseases
 - 2.4.3 Ischemic Stroke
 - 2.4.4 Multiple Sclerosis
 - 2.4.5 Others
- 2.5 Tumor Necrosis Factor Inhibitors Sales by Application
 - 2.5.1 Global Tumor Necrosis Factor Inhibitors Sale Market Share by Application

(2017-2022)

2.5.2 Global Tumor Necrosis Factor Inhibitors Revenue and Market Share by Application (2017-2022)

2.5.3 Global Tumor Necrosis Factor Inhibitors Sale Price by Application (2017-2022)

3 GLOBAL TUMOR NECROSIS FACTOR INHIBITORS BY COMPANY

3.1 Global Tumor Necrosis Factor Inhibitors Breakdown Data by Company

3.1.1 Global Tumor Necrosis Factor Inhibitors Annual Sales by Company (2020-2022)

3.1.2 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Company (2020-2022)

3.2 Global Tumor Necrosis Factor Inhibitors Annual Revenue by Company (2020-2022)

3.2.1 Global Tumor Necrosis Factor Inhibitors Revenue by Company (2020-2022)

3.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Company (2020-2022)

3.3 Global Tumor Necrosis Factor Inhibitors Sale Price by Company

3.4 Key Manufacturers Tumor Necrosis Factor Inhibitors Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Tumor Necrosis Factor Inhibitors Product Location Distribution

3.4.2 Players Tumor Necrosis Factor Inhibitors Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR TUMOR NECROSIS FACTOR INHIBITORS BY GEOGRAPHIC REGION

4.1 World Historic Tumor Necrosis Factor Inhibitors Market Size by Geographic Region (2017-2022)

4.1.1 Global Tumor Necrosis Factor Inhibitors Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Tumor Necrosis Factor Inhibitors Annual Revenue by Geographic Region

4.2 World Historic Tumor Necrosis Factor Inhibitors Market Size by Country/Region (2017-2022)

4.2.1 Global Tumor Necrosis Factor Inhibitors Annual Sales by Country/Region (2017-2022)

- 4.2.2 Global Tumor Necrosis Factor Inhibitors Annual Revenue by Country/Region
- 4.3 Americas Tumor Necrosis Factor Inhibitors Sales Growth
- 4.4 APAC Tumor Necrosis Factor Inhibitors Sales Growth
- 4.5 Europe Tumor Necrosis Factor Inhibitors Sales Growth
- 4.6 Middle East & Africa Tumor Necrosis Factor Inhibitors Sales Growth

5 AMERICAS

- 5.1 Americas Tumor Necrosis Factor Inhibitors Sales by Country
 - 5.1.1 Americas Tumor Necrosis Factor Inhibitors Sales by Country (2017-2022)
 - 5.1.2 Americas Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2022)
- 5.2 Americas Tumor Necrosis Factor Inhibitors Sales by Type
- 5.3 Americas Tumor Necrosis Factor Inhibitors Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Tumor Necrosis Factor Inhibitors Sales by Region
 - 6.1.1 APAC Tumor Necrosis Factor Inhibitors Sales by Region (2017-2022)
 - 6.1.2 APAC Tumor Necrosis Factor Inhibitors Revenue by Region (2017-2022)
- 6.2 APAC Tumor Necrosis Factor Inhibitors Sales by Type
- 6.3 APAC Tumor Necrosis Factor Inhibitors Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Tumor Necrosis Factor Inhibitors by Country
 - 7.1.1 Europe Tumor Necrosis Factor Inhibitors Sales by Country (2017-2022)
 - 7.1.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2022)
- 7.2 Europe Tumor Necrosis Factor Inhibitors Sales by Type

7.3 Europe Tumor Necrosis Factor Inhibitors Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Tumor Necrosis Factor Inhibitors by Country

8.1.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Country (2017-2022)

8.1.2 Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2022)

8.2 Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Type

8.3 Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitors

10.3 Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors

10.4 Industry Chain Structure of Tumor Necrosis Factor Inhibitors

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

- 11.1.2 Indirect Channels
- 11.2 Tumor Necrosis Factor Inhibitors Distributors
- 11.3 Tumor Necrosis Factor Inhibitors Customer

12 WORLD FORECAST REVIEW FOR TUMOR NECROSIS FACTOR INHIBITORS BY GEOGRAPHIC REGION

- 12.1 Global Tumor Necrosis Factor Inhibitors Market Size Forecast by Region
 - 12.1.1 Global Tumor Necrosis Factor Inhibitors Forecast by Region (2023-2028)
 - 12.1.2 Global Tumor Necrosis Factor Inhibitors Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Tumor Necrosis Factor Inhibitors Forecast by Type
- 12.7 Global Tumor Necrosis Factor Inhibitors Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 EPIRUS Biopharmaceuticals
 - 13.1.1 EPIRUS Biopharmaceuticals Company Information
 - 13.1.2 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product Offered
 - 13.1.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.1.4 EPIRUS Biopharmaceuticals Main Business Overview
 - 13.1.5 EPIRUS Biopharmaceuticals Latest Developments
- 13.2 Bionovis
 - 13.2.1 Bionovis Company Information
 - 13.2.2 Bionovis Tumor Necrosis Factor Inhibitors Product Offered
 - 13.2.3 Bionovis Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.2.4 Bionovis Main Business Overview
 - 13.2.5 Bionovis Latest Developments
- 13.3 CASI Pharmaceuticals
 - 13.3.1 CASI Pharmaceuticals Company Information
 - 13.3.2 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Offered
 - 13.3.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)

- 13.3.4 CASI Pharmaceuticals Main Business Overview
- 13.3.5 CASI Pharmaceuticals Latest Developments
- 13.4 Janssen Biotech
 - 13.4.1 Janssen Biotech Company Information
 - 13.4.2 Janssen Biotech Tumor Necrosis Factor Inhibitors Product Offered
 - 13.4.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.4.4 Janssen Biotech Main Business Overview
 - 13.4.5 Janssen Biotech Latest Developments
- 13.5 Momenta Pharmaceuticals
 - 13.5.1 Momenta Pharmaceuticals Company Information
 - 13.5.2 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Offered
 - 13.5.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.5.4 Momenta Pharmaceuticals Main Business Overview
 - 13.5.5 Momenta Pharmaceuticals Latest Developments
- 13.6 GlaxoSmithKline
 - 13.6.1 GlaxoSmithKline Company Information
 - 13.6.2 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product Offered
 - 13.6.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.6.4 GlaxoSmithKline Main Business Overview
 - 13.6.5 GlaxoSmithKline Latest Developments
- 13.7 HanAll Biopharma
 - 13.7.1 HanAll Biopharma Company Information
 - 13.7.2 HanAll Biopharma Tumor Necrosis Factor Inhibitors Product Offered
 - 13.7.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.7.4 HanAll Biopharma Main Business Overview
 - 13.7.5 HanAll Biopharma Latest Developments
- 13.8 Intas Pharmaceuticals
 - 13.8.1 Intas Pharmaceuticals Company Information
 - 13.8.2 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Offered
 - 13.8.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.8.4 Intas Pharmaceuticals Main Business Overview
 - 13.8.5 Intas Pharmaceuticals Latest Developments
- 13.9 LEO Pharma
 - 13.9.1 LEO Pharma Company Information

- 13.9.2 LEO Pharma Tumor Necrosis Factor Inhibitors Product Offered
- 13.9.3 LEO Pharma Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.9.4 LEO Pharma Main Business Overview
- 13.9.5 LEO Pharma Latest Developments
- 13.10 Dexa Medica
 - 13.10.1 Dexa Medica Company Information
 - 13.10.2 Dexa Medica Tumor Necrosis Factor Inhibitors Product Offered
 - 13.10.3 Dexa Medica Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.10.4 Dexa Medica Main Business Overview
 - 13.10.5 Dexa Medica Latest Developments
- 13.11 LG Life Sciences
 - 13.11.1 LG Life Sciences Company Information
 - 13.11.2 LG Life Sciences Tumor Necrosis Factor Inhibitors Product Offered
 - 13.11.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.11.4 LG Life Sciences Main Business Overview
 - 13.11.5 LG Life Sciences Latest Developments
- 13.12 MedImmune
 - 13.12.1 MedImmune Company Information
 - 13.12.2 MedImmune Tumor Necrosis Factor Inhibitors Product Offered
 - 13.12.3 MedImmune Tumor Necrosis Factor Inhibitors Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.12.4 MedImmune Main Business Overview
 - 13.12.5 MedImmune Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Tumor Necrosis Factor Inhibitors Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)
- Table 2. Tumor Necrosis Factor Inhibitors Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)
- Table 3. Major Players of Humira
- Table 4. Major Players of Enbrel
- Table 5. Major Players of Remicade
- Table 6. Major Players of Others
- Table 7. Global Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)
- Table 8. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2022)
- Table 9. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2022) & (\$ million)
- Table 10. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2017-2022)
- Table 11. Global Tumor Necrosis Factor Inhibitors Sale Price by Type (2017-2022) & (USD/Pcs)
- Table 12. Global Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)
- Table 13. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2022)
- Table 14. Global Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2022)
- Table 15. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2017-2022)
- Table 16. Global Tumor Necrosis Factor Inhibitors Sale Price by Application (2017-2022) & (USD/Pcs)
- Table 17. Global Tumor Necrosis Factor Inhibitors Sales by Company (2020-2022) & (K Pcs)
- Table 18. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Company (2020-2022)
- Table 19. Global Tumor Necrosis Factor Inhibitors Revenue by Company (2020-2022) (\$ Millions)
- Table 20. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Company (2020-2022)
- Table 21. Global Tumor Necrosis Factor Inhibitors Sale Price by Company (2020-2022)

& (USD/Pcs)

Table 22. Key Manufacturers Tumor Necrosis Factor Inhibitors Producing Area Distribution and Sales Area

Table 23. Players Tumor Necrosis Factor Inhibitors Products Offered

Table 24. Tumor Necrosis Factor Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Tumor Necrosis Factor Inhibitors Sales by Geographic Region (2017-2022) & (K Pcs)

Table 28. Global Tumor Necrosis Factor Inhibitors Sales Market Share Geographic Region (2017-2022)

Table 29. Global Tumor Necrosis Factor Inhibitors Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 30. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Geographic Region (2017-2022)

Table 31. Global Tumor Necrosis Factor Inhibitors Sales by Country/Region (2017-2022) & (K Pcs)

Table 32. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Country/Region (2017-2022)

Table 33. Global Tumor Necrosis Factor Inhibitors Revenue by Country/Region (2017-2022) & (\$ millions)

Table 34. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Country/Region (2017-2022)

Table 35. Americas Tumor Necrosis Factor Inhibitors Sales by Country (2017-2022) & (K Pcs)

Table 36. Americas Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2017-2022)

Table 37. Americas Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2022) & (\$ Millions)

Table 38. Americas Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2017-2022)

Table 39. Americas Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)

Table 40. Americas Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2022)

Table 41. Americas Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)

Table 42. Americas Tumor Necrosis Factor Inhibitors Sales Market Share by Application

(2017-2022)

Table 43. APAC Tumor Necrosis Factor Inhibitors Sales by Region (2017-2022) & (K Pcs)

Table 44. APAC Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2017-2022)

Table 45. APAC Tumor Necrosis Factor Inhibitors Revenue by Region (2017-2022) & (\$ Millions)

Table 46. APAC Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2017-2022)

Table 47. APAC Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)

Table 48. APAC Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2022)

Table 49. APAC Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)

Table 50. APAC Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2022)

Table 51. Europe Tumor Necrosis Factor Inhibitors Sales by Country (2017-2022) & (K Pcs)

Table 52. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2017-2022)

Table 53. Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2022) & (\$ Millions)

Table 54. Europe Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2017-2022)

Table 55. Europe Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)

Table 56. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2022)

Table 57. Europe Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)

Table 58. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2022)

Table 59. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Country (2017-2022) & (K Pcs)

Table 60. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2017-2022)

Table 61. Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2022) & (\$ Millions)

Table 62. Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue Market Share

by Country (2017-2022)

Table 63. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)

Table 64. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2022)

Table 65. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)

Table 66. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2022)

Table 67. Key Market Drivers & Growth Opportunities of Tumor Necrosis Factor Inhibitors

Table 68. Key Market Challenges & Risks of Tumor Necrosis Factor Inhibitors

Table 69. Key Industry Trends of Tumor Necrosis Factor Inhibitors

Table 70. Tumor Necrosis Factor Inhibitors Raw Material

Table 71. Key Suppliers of Raw Materials

Table 72. Tumor Necrosis Factor Inhibitors Distributors List

Table 73. Tumor Necrosis Factor Inhibitors Customer List

Table 74. Global Tumor Necrosis Factor Inhibitors Sales Forecast by Region (2023-2028) & (K Pcs)

Table 75. Global Tumor Necrosis Factor Inhibitors Sales Market Forecast by Region

Table 76. Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 77. Global Tumor Necrosis Factor Inhibitors Revenue Market Share Forecast by Region (2023-2028)

Table 78. Americas Tumor Necrosis Factor Inhibitors Sales Forecast by Country (2023-2028) & (K Pcs)

Table 79. Americas Tumor Necrosis Factor Inhibitors Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 80. APAC Tumor Necrosis Factor Inhibitors Sales Forecast by Region (2023-2028) & (K Pcs)

Table 81. APAC Tumor Necrosis Factor Inhibitors Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 82. Europe Tumor Necrosis Factor Inhibitors Sales Forecast by Country (2023-2028) & (K Pcs)

Table 83. Europe Tumor Necrosis Factor Inhibitors Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 84. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales Forecast by Country (2023-2028) & (K Pcs)

Table 85. Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue Forecast by

Country (2023-2028) & (\$ millions)

Table 86. Global Tumor Necrosis Factor Inhibitors Sales Forecast by Type (2023-2028) & (K Pcs)

Table 87. Global Tumor Necrosis Factor Inhibitors Sales Market Share Forecast by Type (2023-2028)

Table 88. Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 89. Global Tumor Necrosis Factor Inhibitors Revenue Market Share Forecast by Type (2023-2028)

Table 90. Global Tumor Necrosis Factor Inhibitors Sales Forecast by Application (2023-2028) & (K Pcs)

Table 91. Global Tumor Necrosis Factor Inhibitors Sales Market Share Forecast by Application (2023-2028)

Table 92. Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 93. Global Tumor Necrosis Factor Inhibitors Revenue Market Share Forecast by Application (2023-2028)

Table 94. EPIRUS Biopharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 95. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product Offered

Table 96. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 97. EPIRUS Biopharmaceuticals Main Business

Table 98. EPIRUS Biopharmaceuticals Latest Developments

Table 99. Bionovis Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 100. Bionovis Tumor Necrosis Factor Inhibitors Product Offered

Table 101. Bionovis Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 102. Bionovis Main Business

Table 103. Bionovis Latest Developments

Table 104. CASI Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 105. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Offered

Table 106. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 107. CASI Pharmaceuticals Main Business

Table 108. CASI Pharmaceuticals Latest Developments

- Table 109. Janssen Biotech Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 110. Janssen Biotech Tumor Necrosis Factor Inhibitors Product Offered
- Table 111. Janssen Biotech Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 112. Janssen Biotech Main Business
- Table 113. Janssen Biotech Latest Developments
- Table 114. Momenta Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 115. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Offered
- Table 116. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 117. Momenta Pharmaceuticals Main Business
- Table 118. Momenta Pharmaceuticals Latest Developments
- Table 119. GlaxoSmithKline Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 120. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product Offered
- Table 121. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 122. GlaxoSmithKline Main Business
- Table 123. GlaxoSmithKline Latest Developments
- Table 124. HanAll Biopharma Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 125. HanAll Biopharma Tumor Necrosis Factor Inhibitors Product Offered
- Table 126. HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 127. HanAll Biopharma Main Business
- Table 128. HanAll Biopharma Latest Developments
- Table 129. Intas Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 130. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Offered
- Table 131. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
- Table 132. Intas Pharmaceuticals Main Business
- Table 133. Intas Pharmaceuticals Latest Developments
- Table 134. LEO Pharma Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 135. LEO Pharma Tumor Necrosis Factor Inhibitors Product Offered
- Table 136. LEO Pharma Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$

Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 137. LEO Pharma Main Business

Table 138. LEO Pharma Latest Developments

Table 139. Dexa Medica Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 140. Dexa Medica Tumor Necrosis Factor Inhibitors Product Offered

Table 141. Dexa Medica Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 142. Dexa Medica Main Business

Table 143. Dexa Medica Latest Developments

Table 144. LG Life Sciences Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 145. LG Life Sciences Tumor Necrosis Factor Inhibitors Product Offered

Table 146. LG Life Sciences Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 147. LG Life Sciences Main Business

Table 148. LG Life Sciences Latest Developments

Table 149. MedImmune Basic Information, Tumor Necrosis Factor Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 150. MedImmune Tumor Necrosis Factor Inhibitors Product Offered

Table 151. MedImmune Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 152. MedImmune Main Business

Table 153. MedImmune Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Tumor Necrosis Factor Inhibitors
- Figure 2. Tumor Necrosis Factor Inhibitors Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Tumor Necrosis Factor Inhibitors Sales Growth Rate 2017-2028 (K Pcs)
- Figure 7. Global Tumor Necrosis Factor Inhibitors Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. Tumor Necrosis Factor Inhibitors Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Humira
- Figure 10. Product Picture of Enbrel
- Figure 11. Product Picture of Remicade
- Figure 12. Product Picture of Others
- Figure 13. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type in 2021
- Figure 14. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2017-2022)
- Figure 15. Tumor Necrosis Factor Inhibitors Consumed in Alzheimer's Diseases
- Figure 16. Global Tumor Necrosis Factor Inhibitors Market: Alzheimer's Diseases (2017-2022) & (K Pcs)
- Figure 17. Tumor Necrosis Factor Inhibitors Consumed in Parkinson's Diseases
- Figure 18. Global Tumor Necrosis Factor Inhibitors Market: Parkinson's Diseases (2017-2022) & (K Pcs)
- Figure 19. Tumor Necrosis Factor Inhibitors Consumed in Ischemic Stroke
- Figure 20. Global Tumor Necrosis Factor Inhibitors Market: Ischemic Stroke (2017-2022) & (K Pcs)
- Figure 21. Tumor Necrosis Factor Inhibitors Consumed in Multiple Sclerosis
- Figure 22. Global Tumor Necrosis Factor Inhibitors Market: Multiple Sclerosis (2017-2022) & (K Pcs)
- Figure 23. Tumor Necrosis Factor Inhibitors Consumed in Others
- Figure 24. Global Tumor Necrosis Factor Inhibitors Market: Others (2017-2022) & (K Pcs)
- Figure 25. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2022)
- Figure 26. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by

Application in 2021

Figure 27. Tumor Necrosis Factor Inhibitors Revenue Market by Company in 2021 (\$ Million)

Figure 28. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Company in 2021

Figure 29. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Geographic Region (2017-2022)

Figure 30. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Geographic Region in 2021

Figure 31. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2017-2022)

Figure 32. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Country/Region in 2021

Figure 33. Americas Tumor Necrosis Factor Inhibitors Sales 2017-2022 (K Pcs)

Figure 34. Americas Tumor Necrosis Factor Inhibitors Revenue 2017-2022 (\$ Millions)

Figure 35. APAC Tumor Necrosis Factor Inhibitors Sales 2017-2022 (K Pcs)

Figure 36. APAC Tumor Necrosis Factor Inhibitors Revenue 2017-2022 (\$ Millions)

Figure 37. Europe Tumor Necrosis Factor Inhibitors Sales 2017-2022 (K Pcs)

Figure 38. Europe Tumor Necrosis Factor Inhibitors Revenue 2017-2022 (\$ Millions)

Figure 39. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales 2017-2022 (K Pcs)

Figure 40. Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue 2017-2022 (\$ Millions)

Figure 41. Americas Tumor Necrosis Factor Inhibitors Sales Market Share by Country in 2021

Figure 42. Americas Tumor Necrosis Factor Inhibitors Revenue Market Share by Country in 2021

Figure 43. United States Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 44. Canada Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 45. Mexico Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 46. Brazil Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 47. APAC Tumor Necrosis Factor Inhibitors Sales Market Share by Region in 2021

Figure 48. APAC Tumor Necrosis Factor Inhibitors Revenue Market Share by Regions in 2021

Figure 49. China Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 50. Japan Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 51. South Korea Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 52. Southeast Asia Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 53. India Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 54. Australia Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 55. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Country in 2021

Figure 56. Europe Tumor Necrosis Factor Inhibitors Revenue Market Share by Country in 2021

Figure 57. Germany Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 58. France Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 59. UK Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 60. Italy Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 61. Russia Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 62. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Country in 2021

Figure 63. Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue Market Share by Country in 2021

Figure 64. Egypt Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 65. South Africa Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 66. Israel Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 67. Turkey Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 68. GCC Country Tumor Necrosis Factor Inhibitors Revenue Growth 2017-2022 (\$ Millions)

Figure 69. Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitors in 2021

Figure 70. Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors

Figure 71. Industry Chain Structure of Tumor Necrosis Factor Inhibitors

Figure 72. Channels of Distribution

Figure 73. Distributors Profiles

I would like to order

Product name: Global Tumor Necrosis Factor Inhibitors Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/G8F94D265A31EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8F94D265A31EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970